EUVIMEDEUVIMED entdecken
Multizentrische StudieValidierungsstudieOpen Access · CC BY 4.0

Development and External Validation of a Multivariable Model to Predict Early Minimal Symptom Expression Response in Adult Generalized Myasthenia Gravis Patients Treated With Efgartigimod

Yufang Yang, Tao Liang iD, Mingming Zhao iD, Hongxia Yang, Zhilan Zhao, Lu Yu, Linlin Yan, Siyuan Li, Peng Zhang, Guoyan Qi iD, Jian Yin iD, Zucai Xu iD und 1 weitere

CNS Neuroscience & Therapeutics · 2026

DOI: 10.1002/cns.70746 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift CNS Neuroscience & Therapeutics, 2026. Verfasst von Yufang Yang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Affiliated Hospital of Zunyi Medical University, Zunyi, China. Hauptthemen laut MEDLINE: Myasthenia Gravis. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Guizhou epilepsy basic and clinical research scientific and technological innovation talent team project, Guizhou provincial "hundred-level" innovative talents funds.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Efgartigimod, a neonatal Fc receptor (FcRn) blocker, is approved for generalized Myasthenia Gravis (gMG), but predictors of early response are unclear. Using minimal symptom expression (MSE) as the therapeutic target, we developed and externally validated a clinical model to predict early MSE response after starting efgartigimod. This efgartigimod‐tailored model estimates the baseline probability of achieving early MSE and may assist in individualized treatment selection at therapy initiation.

Methods

We retrospectively analyzed 118 adults with gMG treated at five tertiary centers in China (efgartigimod 10 mg/kg IV weekly ×4). MSE was defined as Myasthenia Gravis–Activities of Daily Living (MG‐ADL) ≤ 1 sustained ≥ 4 weeks; early MSE response was achievement within 4 weeks of initiation. Patients were split into a derivation cohort ( n = 64; three centers) and an external validation cohort ( n = 54; two centers). Candidate predictors included demographics, baseline severity, and laboratory indices. Variables associated with early MSE in univariable analyses entered multivariable logistic regression to construct a nomogram. Discrimination (AUC‐ROC), calibration (curves and Spiegelhalter Z ‐test), and clinical utility (decision curve analysis, DCA) were assessed, with bootstrap internal validation.

Results

Early MSE response occurred in 26/64 derivation and 22/54 validation patients. Lower bulbar MG‐ADL (OR 0.633, p = 0.040), higher FVC% (OR 1.042, p = 0.048), and lower IgG (OR 0.795, p = 0.036) independently predicted early MSE response. The nomogram showed strong discrimination—derivation AUC 0.869 (95% CI 0.797–0.941), bootstrap AUC 0.880 (0.806–0.954), and external AUC 0.839 (0.760–0.919)—and good calibration (Spiegelhalter Z : 1.03, p = 0.303; 0.94, p = 0.347; 1.17, p = 0.242). DCA indicated net benefit across thresholds 0.05–0.82, with validation curves mirroring derivation.

Conclusions

A three‐factor nomogram (bulbar MG‐ADL, FVC%, and serum IgG) provides an efgartigimod‐specific baseline estimate of early sustained‐MSE response probability, which may help neurologists select appropriate candidates, counsel expected benefit, and tailor follow‐up intensity or alternative escalation strategies. Trail Registration Chinese Clinical Trial Registry (ChiCTR2500101971)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myasthenia GravisAdultAgedFemaleHumansMaleMiddle AgedCohort StudiesMultivariate AnalysisReceptors, FcRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

generalized Myasthenia Gravisminimal symptom expressionnomogrampredictive model

Substanzen

Receptors, Fc

Autor:innen und Institutionen

  • Department of Neurology, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
  • Key Laboratory of Brain Function and Brain Disease Prevention and Treatment of Guizhou Province (Qiankehe Foundation-ZSYS(2025)030), Zunyi, China.
  • Department of Neurology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
  • Center for the Diagnosis and Treatment of Myasthenia Gravis, Shijiazhuang People's Hospital, Shijiazhuang, China.
  • Department of Neurology, Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, China.
  • Department of Neurology, Guizhou Provincial People's Hospital, Guiyang, China.

ORCID-Profile: Tao Liang, Mingming Zhao, Guoyan Qi, Jian Yin, Zucai Xu, Zhong Luo

Förderung

  • National Natural Science Foundation of China
  • Guizhou epilepsy basic and clinical research scientific and technological innovation talent team project
  • Guizhou provincial "hundred-level" innovative talents funds
  • National High Level Hospital ClinicalReaearch Funding

Zitieren

APA

Yang, Y., Liang, T., Zhao, M., Yang, H., Zhao, Z., Yu, L., Yan, L., Li, S., Zhang, P., Qi, G., Yin, J., Xu, Z., & Luo, Z. (2026). Development and External Validation of a Multivariable Model to Predict Early Minimal Symptom Expression Response in Adult Generalized Myasthenia Gravis Patients Treated With Efgartigimod. CNS Neuroscience & Therapeutics. https://doi.org/10.1002/cns.70746

Vancouver

Yang Y, Liang T, Zhao M, Yang H, Zhao Z, Yu L, et al. Development and External Validation of a Multivariable Model to Predict Early Minimal Symptom Expression Response in Adult Generalized Myasthenia Gravis Patients Treated With Efgartigimod. CNS Neuroscience & Therapeutics. 2026. doi:10.1002/cns.70746

BibTeX
@article{Yang2026,
  author = {Yang, Yufang and Liang, Tao and Zhao, Mingming and Yang, Hongxia and Zhao, Zhilan and Yu, Lu and Yan, Linlin and Li, Siyuan and Zhang, Peng and Qi, Guoyan and Yin, Jian and Xu, Zucai and Luo, Zhong},
  title = {Development and External Validation of a Multivariable Model to Predict Early Minimal Symptom Expression Response in Adult Generalized Myasthenia Gravis Patients Treated With Efgartigimod},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2026},
  doi = {10.1002/cns.70746}
}
Kostenlos starten →